American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
August 14, 2020
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, Vanessa, and I appreciate all of you being with us today. Before I hand things off to management, there are a few remarks I want to give about forward-looking statements. Please be aware that any comments made during this conference call regarding what the company expects, plans, and anticipates in the future count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Results in reality could differ materially from what those forward-looking statements suggest, owing to a number of significant factors, among them the ones addressed in the company's SEC filings. That covers the annual report on Form 10-K for the year ended December 31, 2019, the Form 10-Q for the period ended March 31, 2020, and the definitive proxy statement for the annual meeting of shareholders held on June 26, 2020. No obligation is taken on by the company to update any information in this conference call. At this point I'd like to hand the call to Ray Stachowiak, Interim President and CEO. Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everyone, and welcome to our conference call covering second quarter 2020 earnings. I’d like to start with a few opening comments. After that, Craig Tagawa, who serves as our COO and CFO, will walk through business and operational results. Our controller, Alexis Wallace, will follow with a financial review. Then Craig, Alexis, Ernie Bates, and I will take your questions. For many companies, the second quarter proved difficult on numerous fronts, and AMS was no different. Treatment delays were greater than we had anticipated, even though volumes rebounded during July. Craig will share additional specifics shortly. In the middle of June, we were pleased to report completion of our purchase of roughly 98% of Gamma Knife Center Ecuador SA’s total outstanding shares from its majority holders. GKC Ecuador is a well-established Gamma Knife operation, started in 2009 as a private clinic to bring advanced stereotactic radiosurgery to Ecuador. It became the country’s first health care institution offering this technology and still runs Ecuador’s only Gamma Knife Center. GKC Ecuador owns its facilities, situated next to one of Ecuador’s leading health care providers in Guayaquil, the nation’s largest city, home to about 2.5 million people. The center also sits not far from our Gamma Knife Center in Peru. Ecuador has been severely affected by the pandemic, but beyond that, we see a substantial chance to grow patient volumes by broadening referral sources, adding more payors, and increasing public sector outreach. We plan to upgrade their Gamma Knife model 4C to a Gamma Knife Perfexion in late 2020 or early 2021; it will rank among the few across all of South America. The gold standard Perfexion system can support higher patient volume by enabling greater ease of use, quicker treatment times, and treatment of a broader range of anatomical structures. This acquisition aligns well with our strategy to diversify our business model and expand further into international markets. We paid an attractive price of 1x historical revenue of $2 million, excluding subsequent working capital payments, which will be a nice addition to our revenue base; in sum, this is an accretive acquisition and a great fit for AMS. Thank you for your continued support of our company. I have great belief in AMS and its opportunities for growth. I’ll now turn over the call to Craig for the second quarter operational review. Craig?
Craig Tagawa
executiveAppreciate that, Ray, and hello everyone this afternoon. Throughout the whole three-month stretch of Q2, COVID-19's impact was greater than we had expected, affecting both our Gamma Knife and PBRT operations. On the Gamma Knife side, revenue declined 28.1% to $2,590,000 compared with the second quarter of 2019, driven by COVID-19's hit to volumes as well as reduced average reimbursement at our retail locations versus what we were paid during the same period a year earlier. Gamma Knife procedure count also dropped 3.1%, coming in at 350 versus 361 in the second quarter of 2019, again due to the COVID-19 pandemic. For the facilities that were up and running, Gamma Knife case counts fell 8.9% versus the equivalent stretch a year earlier, with COVID-19's effects cited as the main cause. Proton therapy brought in $1,401,000, which was basically flat against the same quarter in the prior year. During the second quarter, proton therapy fractions totaled 1,351, down 4.1% from 1,409 in the second quarter of 2019. Compared with this year's first quarter, when we recorded 1,676 fractions, that's a 19.3% drop. Here too, COVID-19's impact was the primary driver behind the second-quarter decline. In the second quarter of 2020, gross margin fell to 22.7% of revenue, down from 33.3% of revenue in the same period of 2019. Because our business carries high fixed costs, the drop in revenue pushed us to a net loss of $483,000 for the second quarter, versus net income of $31,000 in the second quarter of 2019. Several factors drove that decline: reduced Gamma Knife revenue, added pandemic-related expenses, costs tied to moving our annual meeting to a virtual format, and transaction costs stemming from the June acquisition of the Gamma Knife Center in Ecuador. Turning to what lies ahead: in the opening days of July, patient counts at both the PBRT and Gamma Knife sites started climbing, even with the usual seasonal obstacles at play. At PBRT, where the majority of cases involve malignant tumors, the recovery in volume during that month was particularly strong. That said, given COVID-19 flaring up again across multiple regions of the country, we can't say with confidence when case volumes might settle into a lasting, steady pattern. As for the third quarter, we anticipate recording the final transaction expenses tied to the Ecuador acquisition. While the virus has likewise weighed on case volumes in Ecuador, our expectation is that once COVID-19 passes, those volumes will contribute positively to earnings. The planned upgrade at Lovelace Medical Center—swapping the Gamma Knife Perfexion for the Icon platform—is still set for September. Talks about further upgrades and reloads are ongoing too, though scheduling those has proven tricky. As we've noted before, we're also still in conversations with a number of parties who've expressed interest in additional PBRT, Gamma Knife and MRI-LINAC placements. And lastly, as today's press release states and as we've covered during our past 3 quarterly calls, CMS introduced a proposed mandatory payment model for radiation oncology services back in July 2019. The idea behind it is to trial an episodic payment structure—a bundled payment—among selected radiation therapy providers and suppliers. CMS estimates that roughly 40% of radiation oncology providers will be chosen at random and brought into this model, while about 60% will keep getting reimbursed under the existing fee-for-service approach. This proposed model would substantially change how CMS pays for radiation oncology services. For that 60% of centers left out of the proposed model, Medicare reimbursement in 2021 for the most frequently used proton therapy delivery codes is proposed to rise by approximately 4.9%, pending a final determination, and to fall 0.1% for the Gamma Knife. That said, as one would expect given the current environment, we still have not gotten any further information from CMS regarding the timing and selection details of the proposed payment model. As a result, we can't predict how the proposed rule's adoption would affect us. Still, lower reimbursement rates—or changes to how radiosurgery and radiation therapy reimbursements are methodized and administered—might damage our revenue and financial outcomes. Should we learn anything new, we'll share it with you. I'll now pass things along to Alexis for the full financial rundown. Alexis?
Alexis Wallace
executiveThanks, Craig, and good afternoon, everyone. Before I begin my prepared comments, I'd like to direct everyone to the earnings press release for our second quarter, which was issued earlier today. If you don't have a copy, it's available on our website, ashs..com, under the Press Releases section in the Investors tab. Now, turning to our results for the second quarter. For the three months that ended June 30, 2020, total revenue declined 23.2% to $3,991,000, compared with $5,197,000 in revenue for the second quarter of 2019. This quarter, we didn't bring in any revenue from IGRT equipment. In last year's second quarter, that figure was $188,000. The reason for the change is that the equipment had been completely depreciated and then sold after the company's contract ended on December 31, 2019. As for our Proton Therapy system that's installed at Orlando Health in Florida, second quarter revenue came to $1,401,000, which is a decline of 0.6%. During the same period in 2019, revenue was $1,409,000. Turning to our Gamma Knife operations, revenue fell 28.1% to $2,590,000 in the second quarter of 2020. In the second quarter of 2019, that number stood at $3,600,000. The drop was driven by lower volumes as well as reduced average reimbursement at our retail sites, which happened because a larger share of patients were Medicare patients. In the second quarter of 2020, gross margin fell to $907,000, representing 22.7% of revenue. For the same period in 2019, gross margin stood at $1,729,000, or 33.3% of revenue. The net loss for Q2 2020 was $483,000, equal to $0.08 per share. By contrast, net income of $31,000, or $0.01 per share, was recorded in the second quarter of 2019. Weighted average common shares outstanding on a fully diluted basis totaled 6,077,000 in Q2 2020 and 5,906,000 in Q2 2019. Adjusted EBITDA, which is a non-GAAP financial measure, reached $1,437,000 during the second quarter of 2020, versus $2,465,000 in the comparable quarter of 2019. The main reason for that drop was the net loss we recorded, combined with reduced depreciation and amortization on the company's IGRT equipment, which finished depreciating during 2019's fourth quarter. As of June 30, our cash, cash equivalents and restricted cash totaled $4,409,000, versus $1,779,000 on December 31, 2019. Shareholders' equity came to $30,973,000 at June 30, 2020, which works out to $5.44 for each outstanding share. For comparison, shareholders' equity on December 31, 2019, was $31,811,000, or $5.47 per outstanding share. That concludes the formal part of what we have to present. Vanessa, we'd now like to give the call back to you so you can take questions.
Tony Marchese
analystRay, best wishes on stepping into the top job. Let me ask you something. You've held shares for quite a while. My guess is your basis in the position sits about $1 above the current price. You've served on the Board. Right now the shares change hands at 40% of book value, and maybe tangible book is somewhat lower — say $5. What I wonder, from where you sit, both as an owner and a Board member who is now acting CEO, is what you believe the market is telling us or failing to see? It's tough to locate a company whose stock isn't headed toward shutting down. And obviously you aren't that, or it wouldn't be changing hands at this level of book value or this percentage of book value. So now that you've had some time in the seat, I'm simply curious about your read on what it will take to get the shares to at minimum trade at — which would mean no less than a double — tangible book. Hello?
Ray Stachowiak
executiveAnthony, my apologies, I had myself muted there for a moment.
Tony Marchese
analystAll right. That's fine. I figured my phone was the problem.
Ray Stachowiak
executiveNo, my apologies for that. Anthony, I appreciate you raising that question. I'm happy you mentioned it. Like you said, I've held stock in American Shared Hospital Services for a long time. And honestly, one thing that drew me to invest is this matter of tangible book value sitting way above our market value; and companies with $25 million to $30 million plus of tangible equity that don't carry a market value above their book value aren't something you see often. What I typically expect to see is that ratio, market value over book value, coming in above one. And in our situation, that's definitely not the case. That's among the reasons I put money in. Why has it stayed that way? For a few of the reasons, I can only guess. We haven't had a stretch of earnings that was sustained. And our results, I'd say, have been uneven across the last several years. And I believe there's a chance to fix that. I believe it will take a while; but I'm somewhat bullish that we can pull that off. The majority of publicly traded companies have a price-to-earnings ratio that people watch. And is it out of line, how far off is that P/E ratio compared with the rest of the marketplace? Well, having a P/E ratio is tough when the denominator is 0. So I think among the first things we need to concentrate on is how we can start generating some profits. That's my answer.
Ray Stachowiak
executiveAlright, I appreciate all of you being here with us today. If anything comes up, reach out to us prior to our Q3 call, which happens in the middle of November. Take care of yourselves, remain healthy. Enjoy your weekend. So long.
Operator
operatorAppreciate it, everyone. That wraps up the call for today. Thanks for joining in. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.